Document is current
Any future updates will be listed below
-
Authors
Muraoka, Shinsuke https://orcid.org/0000-0003-4225-110X
Izumi, Takashi
Takeuchi, Issei
Nishihori, Masahiro
Goto, Shunsaku
Imaoka, Eiki
Kanamori, Fumiaki
Uda, Kenji
Sakamoto, Yusuke
Yokoyama, Kinya
Ando, Masahiko
Kuwatsuka, Yachiyo
Nishida, Kazuki
Chretien, Basile
Saito, Ryuta
,
Maesawa, Satoshi
Shimato, Shinji
Kinkori, Takeshi
Asai, Takumi
Suzuki, Osamu
Maki, Hideki
Hattori, Kenichi
Yoshida, Mitsuhiro
Takasu, Shuntaro
Hasegawa, Toshinori
Sugita, Ryotaro
Ito, Satoshi
Tsukada, Tetsuya
Yamanouchi, Takashi
Kano, Takahisa
Okada, Takeshi
Wakabayashi, Kenichi
Iwasaki, Masashige
Hayashi, Shigemasa
Tachibana, Eiji
-
Funding
Funding for this research was provided by:
Nagoya University Hospital Funding for Clinical Research
Japan Research Foundation for Clinical Pharmacology
Nagoya University
- License Information
-
More Information
Article History
Received: 27 October 2025
Accepted: 5 March 2026
First Online: 2 April 2026
Conflicts of Interest
: The authors declare that there are potential conflicts of interest with respect to the research, authorship, and/or publication of this article. RS received funding from NXERA Pharma Japan, the company that markets clazosentan, but was not involved in the interpretation or analysis of the results presented in this paper. The other authors declare no competing interests.
: Written informed consent will be obtained from all participants or their legally authorized representatives before any study-specific procedures.
: This study was approved by the Institutional Review Board (IRB) of Nagoya University Hospital (approval number: 2024-0341) and will be conducted in accordance with the Declaration of Helsinki.
: SAVIOR study, , jRCT1041240128 (version 1.0), Registered 22 November 2024.
